Status:

RECRUITING

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Lead Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions:

Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-2005 for Intravesical perfusion in patients with intermediate...

Eligibility Criteria

Inclusion

  • Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;
  • ≥18 years of age, either sex;
  • Previous pathological biopsy was diagnosed as intermediate or high-risk NMIBC ;
  • ECOG performance status of 0-1;
  • Life expectancy ≥ 2 years;
  • Adequate bone marrow and organ function.

Exclusion

  • Received TURBT or other surgical treatment or radiotherapy for bladder lesions within 2 weeks before the first administration;
  • Patients who were receiving treatment in other clinical trials or less than 4 weeks from the end of the first administration in this study;
  • History of serious cardiovascular and cerebrovascular diseases;
  • Severe infection within 2 weeks prior to the first dose;
  • Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0;
  • Oversize surgery or severe trauma within 4 weeks before the first use of research drugs;
  • Previously received any TNFR agonist antibody therapy, such as OX40, CD137, CD27, CD357 antibodies.

Key Trial Info

Start Date :

November 28 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

September 30 2027

Estimated Enrollment :

170 Patients enrolled

Trial Details

Trial ID

NCT06108492

Start Date

November 28 2023

End Date

September 30 2027

Last Update

December 3 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Fudan University Zhongshan Hospital

Shanghai, Shanghai Municipality, China, 200032

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) | DecenTrialz